MedPath

HOPE PHARMACEUTICALS

๐Ÿ‡ฎ๐Ÿ‡ณIndia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:1

Trial Phases

2 Phases

Phase 2:3
Phase 3:1

Drug Approvals

5

FDA:3
CANADA:1

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)โ€ข Click on a phase to view related trials

Phase 2
3 (75.0%)
Phase 3
1 (25.0%)

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

Phase 2
Withdrawn
Conditions
COVID-19
Acute Respiratory Distress Syndrome
Acute Respiratory Failure
Interventions
Drug: Normal Saline
First Posted Date
2020-05-26
Last Posted Date
2020-09-16
Lead Sponsor
Hope Pharmaceuticals
Registration Number
NCT04401527
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Participating Research Facility, Fort Worth, Texas, United States

Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Terminated
Conditions
Calciphylaxis
First Posted Date
2017-10-24
Last Posted Date
2018-11-20
Lead Sponsor
Hope Pharmaceuticals
Target Recruit Count
5
Registration Number
NCT03319914
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Veterans Administration Medical Center, Albany, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland Clinic, Cleveland, Ohio, United States

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

Phase 3
Terminated
Conditions
Calciphylaxis
Interventions
Drug: Placebo-Normal Saline
First Posted Date
2017-05-12
Last Posted Date
2020-05-19
Lead Sponsor
Hope Pharmaceuticals
Target Recruit Count
29
Registration Number
NCT03150420
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic, Jacksonville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northwestern University Hospital, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Loyola University Medical Center, Maywood, Illinois, United States

and more 17 locations

Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage

Phase 2
Terminated
Conditions
Subarachnoid Hemorrhage
Interventions
First Posted Date
2014-06-27
Last Posted Date
2018-03-30
Lead Sponsor
Hope Pharmaceuticals
Target Recruit Count
6
Registration Number
NCT02176837
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Virginia Medical Center, Charlottesville, Virginia, United States

Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm

Phase 2
Completed
Conditions
Subarachnoid Hemorrhage
Interventions
First Posted Date
2009-04-01
Last Posted Date
2020-05-21
Lead Sponsor
Hope Pharmaceuticals
Target Recruit Count
19
Registration Number
NCT00873015
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Virginia Health System Medical Center, Charlottesville, Virginia, United States

News

Oops! Someting went wrong.
An unexpected error occurred, sorry about that. We've been notified and will get started on a fix.
An error occurred while fetching news

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.